Advertisement
Screener

VAXCYTE, INC. (PCVX) Graph

PCVX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $267.85M; Operating expenses $302.78M; Income tax $0.00; Net income -$284.30M.
  • 2026-03-31: Research and development $312.78M; Operating expenses $345.85M; Income tax $0.00; Net income -$320.62M.
  • 2025-12-31: Research and development $242.06M*; Operating expenses $274.28M*; Income tax $0.00*; Net income $519.35M*.
  • 2025-09-30: Research and development $209.93M; Operating expenses $242.38M; Income tax $0.00; Net income -$212.83M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$267.85M$302.78M$0.00-$284.30M
2026-03-31$312.78M$345.85M$0.00-$320.62M
2025-12-31$242.06M*$274.28M*$0.00*$519.35M*
2025-09-30$209.93M$242.38M$0.00-$212.83M
2025-06-30$194.18M$226.22M$0.00-$166.57M
2025-03-31$148.13M$180.79M$0.00-$140.72M
2024-09-30$116.94M$139.92M$0.00-$103.12M
2024-06-30$131.51M$152.98M$0.00-$128.70M
2024-03-31$94.59M$114.47M$0.00-$95.02M
2023-09-30$97.42M$113.03M$0.00-$92.66M
2023-06-30$72.69M$87.15M$0.00-$68.34M
2023-03-31$58.08M$71.19M$0.00-$60.46M
2022-09-30$47.68M$58.58M$0.00-$57.92M
2022-06-30$38.47M$47.89M$0.00-$48.53M
2022-03-31$31.68M$39.22M$0.00-$38.99M
2021-09-30$20.43M$26.95M$0.00-$26.61M
2021-06-30$17.65M$23.73M$0.00-$23.68M
2021-03-31$17.26M$23.14M$0.00-$21.22M
2020-12-31$14.66M$19.45M(m)-$20.74M
2020-09-30$16.41M$21.31M$0.00-$21.02M
2020-06-30$18.18M$21.22M$0.00-$20.32M
2020-03-31$24.32M$27.60M(m)-$27.14M
2019-12-31$13.38M$15.84M(m)-$14.62M
2019-09-30$9.63M$12.14M(m)-$11.32M
2019-06-30$9.97M$12.23M(m)-$10.66M
2019-03-31$12.63M$13.94M(m)-$13.67M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$580.63M$648.63M$0.00-$604.92M
2025-06-30$342.31M$407.01M$0.00-$307.29M
2024-06-30$226.09M$267.45M$0.00-$223.72M
2023-06-30$130.77M$158.34M$0.00-$128.80M
2022-06-30$70.15M$87.11M$0.00-$87.52M
2021-06-30$34.91M$46.87M$0.00-$44.90M
2020-06-30$42.49M$48.82M$0.00-$47.46M
2019-06-30$22.59M$26.18M(m)-$24.34M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$552.25M$649.39M$0.00-$520.12M
2024-09-30$343.03M$407.38M$0.00-$326.85M
2023-09-30$228.19M$271.37M$0.00-$221.47M
2022-09-30$117.83M$145.68M$0.00-$145.44M
2021-09-30$55.34M$73.82M$0.00-$71.51M
2020-09-30$58.90M$70.13M$0.00-$68.48M
2019-09-30$32.23M$38.31M(m)-$35.65M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$794.31M$923.67M$0.00-$766.63K
2024-12-31$476.64M$569.55M$0.00-$463.93K
2023-12-31$332.34M$468.04M$0.00-$402.27K
2022-12-31$169.45M$232.26M(m)-$223.49K
2021-12-31$78.41M$103.67M(m)-$100.08K
2020-12-31$73.56M$89.58M(m)-$89.22M
2019-12-31$45.61M$54.15M(m)-$50.27M
2018-12-31$30.14M$35.53M(m)-$29.48M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
REPLIGEN CORP (RGEN)United States$10.755B185.31
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
CRISPR Therapeutics AG (CRSP)$5.390B-11.68